DUBLIN, July 20, 2016 /PRNewswire/ -- Perrigo
Company plc ("Perrigo" or the "Company") (NYSE: PRGO; TASE), a
leading global provider of Quality Affordable Healthcare
Products®, today announced the departure of
Douglas Boothe, Executive Vice
President and General Manager, Rx Pharmaceuticals. John Wesolowski, Senior Vice President of Rx
Commercial Operations, will assume the role of Acting General
Manager, Rx Pharmaceuticals.
Perrigo's Chief Executive Officer John
T. Hendrickson said, "John
Wesolowski has the full confidence of our executive team to
advance the business. He has 24 years of generic and specialty
pharma experience and brings strong customer relationships, a deep
understanding of our industry, and steady commercial leadership. We
are conducting a thorough search process for a business leader who
will focus on performance across our Rx portfolio and invest for
future long-term growth. We are examining our overall Rx strategy
and will continue to drive this organization to execute in the best
interests of our shareholders."
As Senior Vice President of Rx Commercial Operations, Mr.
Wesolowski oversees Rx sales, marketing, contracts, and customer
service. In addition to these responsibilities, his role will now
also include oversight of Rx finance and business development.
Prior to joining Perrigo as Vice President of Commercial Operations
in February 2004, Mr. Wesolowski
served in several customer-facing roles at E. Fougera and Company
from 1993 to 2004.
Mr. Hendrickson concluded, "We thank Doug for his contributions
and wish him well in his future endeavors."
About Perrigo
Perrigo Company plc, a top five global over-the-counter ("OTC")
consumer goods and pharmaceutical company, offers patients and
customers high quality products at affordable prices. From its
beginnings in 1887 as a packager of generic home remedies, Perrigo,
headquartered in Ireland, has
grown to become the world's largest manufacturer of OTC products
and supplier of infant formulas for the store brand market. The
Company is also a leading provider of generic extended topical
prescription products and receives royalties from Multiple
Sclerosis drug Tysabri®. Perrigo provides Quality Affordable
Healthcare Products® across a wide variety of product categories
and geographies primarily in North
America, Europe, and
Australia, as well as other
markets, including Israel,
China and Latin America. Visit Perrigo online at
(http://www.perrigo.com).
Forward-Looking Statements
Certain statements in this press release are "forward-looking
statements." These statements relate to future events or the
Company's future financial performance and involve known and
unknown risks, uncertainties and other factors that may cause the
actual results, levels of activity, performance or achievements of
the Company or its industry to be materially different from those
expressed or implied by any forward-looking statements. In some
cases, forward-looking statements can be identified by terminology
such as "may," "will," "could," "would," "should," "expect,"
"plan," "anticipate," "intend," "believe," "estimate," "predict,"
"potential" or the negative of those terms or other comparable
terminology. The Company has based these forward-looking statements
on its current expectations, assumptions, estimates and
projections. While the Company believes these expectations,
assumptions, estimates and projections are reasonable, such
forward-looking statements are only predictions and involve known
and unknown risks and uncertainties, many of which are beyond the
Company's control, including the timing, amount and cost of share
repurchases, future impairment charges, our ability to achieve our
guidance and the ability to execute and achieve the desired
benefits of announced initiatives. These and other important
factors, including those discussed under "Risk Factors" in the
Company's Form 10-KT for the six-month period ended December 31, 2015, and form 10-Q for the quarter
ended April 2, 2016 as well as the
Company's subsequent filings with the SEC, may cause actual
results, performance or achievements to differ materially from
those expressed or implied by these forward-looking statements. The
forward-looking statements in this press release are made only as
of the date hereof, and unless otherwise required by applicable
securities laws, the Company disclaims any intention or obligation
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Logo
- http://photos.prnewswire.com/prnh/20120301/DE62255LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/perrigo-announces-leadership-change-in-rx-pharmaceuticals-segment-300301840.html
SOURCE Perrigo Company plc